Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.

Autor:	D'Souza JW; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Hensley H; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Doss M; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.; Nuclear Medicine, Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and., Beigarten C; ImaginAb Inc., Inglewood, California., Torgov M; ImaginAb Inc., Inglewood, California., Olafsen T; ImaginAb Inc., Inglewood, California., Yu JQ; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.; Nuclear Medicine, Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and., Robinson MK; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania matthew.robinson@fccc.edu.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Jan; Vol. 58 (1), pp. 175-180. Date of Electronic Publication: 2016 Aug 18.
DOI:	10.2967/jnumed.116.178780
Abstrakt:	Antibodies, and engineered antibody fragments, labeled with radioisotopes are being developed as radiotracers for the detection and phenotyping of diseases such as cancer. The development of antibody-based radiotracers requires extensive characterization of their in vitro and in vivo properties, including their ability to target tumors in an antigen-selective manner. In this study, we investigated the use of Cerenkov luminescence imaging (CLI) as compared with PET as a modality for evaluating the in vivo behavior of antibody-based radiotracers. Methods: The anti-prostate-specific membrane antigen (PSMA) huJ591 antibody (IgG; 150 kDa) and its minibody (Mb; 80 kDa) format were functionalized with the chelator 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) and radiolabeled with the positron-emitting radionuclide 64 Cu (half-life, 12.7 h). Immunoreactive preparations of the radiolabeled antibodies were injected into NCr nu/nu mice harboring PSMA-positive CWR22Rv1 and PSMA-negative PC-3 tumor xenografts. Tumor targeting was evaluated by both PET and CLI. Results: 64 Cu-NODAGA-PSMA-IgG and 64 Cu-NODAGA-PSMA-Mb retained the ability to bind cell surface PSMA, and both radiotracers exhibited selective uptake into PSMA-positive tumors. Under the experimental conditions used, PSMA-selective uptake of 64 Cu-NODAGA-PSMA-IgG and 64 Cu-NODAGA-PSMA-Mb was observed by CLI as early as 3 h after injection, with tumor-to-background ratios peaking at 24 (IgG) and 16 (Mb) h after injection. Targeting data generated by CLI correlated with that generated by PET and necropsy. Conclusion: CLI provided a rapid and simple assessment of the targeting specificity and pharmacokinetics of the antibody-based PET radiotracers that correlated well with the behavior observed by standard PET imaging. Moreover, CLI provided clear discrimination between uptake kinetics of an intact IgG and its small-molecular-weight derivative Mb. These data support the use of CLI for the evaluation of radiotracer performance. (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu